Corporate Banner
Satellite Banner
Metabolomics & Lipidomics
Scientific Community
Become a Member | Sign in
Home>News>This Article

Metabolon’s Quantose™ IR Test Featured in Five Poster Presentations at 2012 ADA Meeting

Published: Tuesday, June 12, 2012
Last Updated: Tuesday, June 12, 2012
Bookmark and Share
Clinical data demonstrate test’s effectiveness in stratifying prediabetic patients based on insulin resistance levels.

Metabolon, Inc. has announced that the clinical utility of the Company’s lead diagnostic product Quantose™ IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

Quantose IR is a fasting blood test to measure insulin resistance (IR). The test measures levels of three novel non-glycemic biomarkers and insulin to detect prediabetes earlier and with greater sensitivity than traditional glycemic markers such as glucose and Hemoglobin A1C.

“This marks our fourth consecutive ADA annual meeting and our expanded presence this year reflects our Company’s continued focus on developing diagnostic tests related to metabolic disease,” said John Ryals, President and CEO of Metabolon.

Ryals continued, “As insulin resistance is known to precede Type 2 diabetes by up to 10 years, Quantose IR offers clinicians a tool for identifying patients at greatest risk for disease progression long before glycemic markers show evidence of dysregulation. Clinicians seeking to intervene in this high-risk group will be provided unique pathophysiological insight helpful in tailoring treatments to individual patients. Our Quantose IR test also provides a useful therapeutic monitoring tool to complement traditional markers in gauging treatment effectiveness due to its non-glycemic markers tracking so closely with changing insulin sensitivity.”

The following five abstracts related to Metabolon’s ongoing research and development efforts associated with Quantose IR will be featured at the ADA meeting:

“Early metabolic markers of the development of dysglycemia and Type 2 diabetes and their physiological significance”
• Alpha-hydroxybutyrate (AHB) and linoleoyl-glycerophosphocholine (L-GPC) are described as novel circulatory markers of insulin resistance, with clinical outcome data demonstrating their predictive risk to prediabetes and Type 2 diabetes and response to intervention.

Additional studies are presented that examine the Quantose IR biomarker’s physiological significance such as their bioactivity on insulin secretion. Abstract # 1600-P, to be presented by Dr. Walter Gall during the Monday, June 11th 12-2pm poster session.

“Pioglitazone improves insulin sensitivity by modulating novel biomarkers in impaired glucose tolerance” (Audio poster tour)
• Top-ranking insulin sensitivity biomarkers are measured in the T2D prevention study ACT NOW. The purpose of the study was to describe the response of the novel Quantose IR metabolites and its algorithm IR signature to pioglitazone pharmacotherapy and provide context of these observations in a diabetes prevention clinical setting.

Abstract # 1182-P, to be presented by Dr. Walter Gall during the Saturday, June 9th 11:30am-1:30pm poster session and the Sunday, June 10th 12-1pm guided audio tour.
“Metabolomic profile associated with hepatic insulin resistance in nondiabetic subjects: results from RISC study” (Audio poster tour)
• Quantose IR metabolites AHB and L-GPC are associated with hepatic insulin resistance, non-alcoholic fatty liver disease and NASH, further validating the clinical importance of measuring these novel biomarkers associated with IR-related disease outcomes. Abstract # 1791-P, to be presented by Dr. Amalia Gastadelli during the Monday, June 11th 12-2pm poster session.

“Effect of aging and exercise on novel insulin sensitivity marker linoleoyl-glycerophosphocholine” (Audio poster tour)
• Lifestyle intervention study with sedentary IR subjects demonstrate the response of Quantose IR metabolites AHB and L-GPC to aerobic exercise and further show associations of L-GPC with aging.

Abstract # 714-P, to be presented by Dr. Jose de Jesus Garduno Garcia during the Monday, June 11th 12-2pm poster session and the Monday, June 11th 1-2pm guided audio tour.

“Genetic variants associated with diabetes related circulating metabolite levels and their role in type 2 diabetes and insulin sensitivity”
• Genome-wide association studies were carried out with the RISC and Botnia prospective studies to identify and validate associations of genes and metabolites related to glycine, the top-ranking amino acid related to insulin sensitivity and proximal to Quantose IR metabolite AHB biosynthesis. Abstract # 1526-P, to be presented by Dr. Weijia Xie during the Monday, June 11th 12-2pm poster session.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,700+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Metabolon Launches Strategic Outsourcing Programs Focused On Disease Metabolism
Metabolon’s partners will collaborate toward shared objectives through this program.
Monday, October 15, 2012
Metabolon Files Patent Infringement Lawsuit against Stemina
The lawsuit requests monetary damages as well as an order permanently enjoining Stemina from continued acts of infringement.
Tuesday, August 28, 2012
Metabolon Strengthens Metabolomics Leadership with Acquisition of Lipomics Technologies
Gains proprietary lipids technology platform and further opportunities for diagnostics, personalized medicine and commercial services.
Friday, August 03, 2012
Metabolon Technology Now Available in Germany
The Helmholtz Zentrum Muenchen, Research Center for Environmental Health in Neuherberg, Germany, has successfully completed Metabolon’s validation requirements.
Friday, July 13, 2012
Metabolon’s Shanghai Jiao Tong University Lab Receives Validation
The joint metabolomics laboratory passed the quality control processes and has officially started operation.
Monday, May 14, 2012
Takeda and Metabolon Initiate Research Collaboration
Multiyear research alliance to discover novel targets and biomarkers.
Wednesday, April 18, 2012
Metabolon Awarded Analytical Methods Patent
The patented method enables the researcher to process, analyze and interpret data more efficiently.
Thursday, March 29, 2012
Metabolon Receives Accreditation by College of American Pathologists
Metabolon, Inc. announces that they have received laboratory accreditation from the College of American Pathologists (CAP).
Tuesday, December 06, 2011
Metabolomics Insight into Periodontal Disease Published in the Journal of Dental Research
Data reveal altered host-bacteria interactions associated with periodontitis.
Monday, October 24, 2011
Metabolon and SJTU Open Metabolomics Lab in China
Shanghai facility is company’s first foray into Asia.
Tuesday, October 18, 2011
Genome Wide Association Study Published in Nature
Metabolon, Inc. announces the publication of “Human Metabolic Individuality in Biomedical and Pharmaceutical Research” in the journal Nature.
Tuesday, September 20, 2011
Metabolon Secures $13 Million in Series D Financing
New investor Keating Capital, Inc. joins existing investors including Sevin Rosen Funds, Aurora Funds, Harris & Harris Group, Syngenta Ventures, Fletcher Spaght and Fulcrum Financial Partners in the round.
Tuesday, August 30, 2011
Two Studies Provide Insight into Kidney Cancer
Metabolon, Inc. announces the publication of studies in two peer-reviewed journals that support the use of metabolomics in the diagnosis and treatment of kidney cancer.
Tuesday, August 16, 2011
Research into Dietary Leucine
Metabolon, Inc. announces the publication of “Dietary Leucine - An Environmental Modifier of Insulin Resistance Acting on Multiple Levels of Metabolism” in PLoS One.
Tuesday, July 19, 2011
USPTO Grants Two New Patents to Metabolon
Metabolon currently holds 17 US Patents related to its biochemical profiling methods, data analysis solutions and biomarkers for disease and toxicity.
Monday, June 20, 2011
Scientific News
New Protein Cleanup Factors Found to Control Bacterial Growth
UMass Amherst researchers characterize previously mysterious proteolysis factors.
New Treatment for Obesity Developed
Researchers at the University of Liverpool, working with a global healthcare company, have helped develop a new treatment for obesity.
How Cell Growth Triggers Cell Division
Researchers in Jan Skotheim's lab have discovered a previously unknown mechanism that controls how large cells grow, an insight that could one day provide insight into attacking diseases such as cancer.
Metabolomic Platform Reveals Fundamental Flaw in Common Lab Technology
A new study led by scientists at The Scripps Research Institute (TSRI) shows that a technology used in thousands of laboratories, called gas chromatography mass spectrometry (GC-MS), fundamentally alters the samples it analyzes.
Newly Identified Biochemical Pathway Could Be Target for Insulin Control
Researchers at Duke Medicine and the University of Alberta are reporting the identification of a new biochemical pathway to control insulin secretion from islet beta cells in the pancreas, establishing a potential target for insulin control.
Dirty,Crusty Meals Fit for (Long-Dormant) Microbes
Researchers apply the latest analytical techniques to further our understanding of desert biocrusts.
CSI -- On The Metabolite's Trail
Bioinformaticians at the University of Jena make the most efficient search engine for molecular structures available online.
Developing a Breathalyzer-Type Low Blood Sugar Warning Device For Diabetes
A multidisciplinary team of researchers at Indiana University-Purdue University Indianapolis has been awarded a $738,000 National Science Foundation grant to develop a breathalyzer-type device to detect the onset of hypoglycemia, or low blood sugar episodes, in people with diabetes.
Identifying The 'Dimmer Switch' Of Diabetes
University of Alberta research gives new insight into what causes Type 2 diabetes.
10 to 1: Bugs Win in NASA study
Bugs are winning out, and that's a good thing according to NASA's Human Research Program.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,700+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos